Our mission is to provide hope for families by delivering innovative and accessible solutions to transform the lives of patients and their families living with rare cholestatic liver diseases. We succeed in our mission only if our products reach the patients who will benefit from them, so we prioritize patient access in everything we do.
In planning for our first potential commercial product approval, we worked to determine the price of our medicines for rare diseases based on their value and impact on patients, families, caregivers, providers, payors and society. As such, we are guided by the following principles:
In our commitment to ensuring that eligible patients can access Bylvay™ (odevixibat) in a fully compliant manner, we will work within the relevant regulatory processes for each country to meet our ongoing commitment to patients and to support the PFIC community.
For patients in the U.S., Albireo has built a customized and company-run patient services program called AlbireoAssist™. To learn more about the program, visit AlbireoAssist.com.
For patients outside the U.S., access to Bylvay in certain countries is now available through our Managed Access Program. For patients in Germany, we also offer Albireo Assist Germany, a patient support program for patients and caregivers of children diagnosed with PFIC to accompany Bylvay and optimize outcomes.